Apellis Pharmaceuticals, Inc. (NASDAQ:APLS) Insider Caroline Baumal Sells 2,816 Shares

Apellis Pharmaceuticals, Inc. (NASDAQ:APLS) insider Caroline Baumal sold 2,816 shares of the stock in a transaction dated Monday, January 6th. The stock was sold at an average price of $33.81, for a total transaction of $95,208.96. Following the transaction, the insider now owns 55,560 shares in the company, valued at approximately $1,878,483.60. The trade was a 4.82 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink.

Apellis Pharmaceuticals Stock Performance

Apellis Pharmaceuticals stock opened at $33.00 on Thursday. Apellis Pharmaceuticals, Inc. has a 12-month low of $24.34 and a 12-month high of $73.80. The company has a debt-to-equity ratio of 1.91, a current ratio of 4.36 and a quick ratio of 3.73. The company has a market capitalization of $4.10 billion, a price-to-earnings ratio of -16.26 and a beta of 0.94. The firm’s fifty day moving average price is $31.66 and its 200 day moving average price is $33.83.

Apellis Pharmaceuticals (NASDAQ:APLS) last announced its earnings results on Tuesday, November 5th. The company reported ($0.46) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.32) by ($0.14). Apellis Pharmaceuticals had a negative return on equity of 103.11% and a negative net margin of 34.97%. The business had revenue of $196.83 million for the quarter, compared to analysts’ expectations of $200.00 million. During the same period in the previous year, the firm posted ($1.17) earnings per share. The firm’s revenue was up 78.3% compared to the same quarter last year. On average, research analysts forecast that Apellis Pharmaceuticals, Inc. will post -1.72 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

A number of equities analysts have weighed in on the stock. William Blair initiated coverage on shares of Apellis Pharmaceuticals in a research note on Wednesday, October 16th. They set an “outperform” rating on the stock. Wells Fargo & Company cut their target price on Apellis Pharmaceuticals from $43.00 to $30.00 and set an “equal weight” rating on the stock in a research report on Wednesday, November 6th. Bank of America lowered their price target on Apellis Pharmaceuticals from $61.00 to $47.00 and set a “buy” rating for the company in a research report on Wednesday, November 6th. JPMorgan Chase & Co. cut their price objective on Apellis Pharmaceuticals from $64.00 to $57.00 and set an “overweight” rating on the stock in a report on Friday, September 13th. Finally, The Goldman Sachs Group cut Apellis Pharmaceuticals from a “buy” rating to a “neutral” rating and set a $36.00 target price for the company. in a report on Tuesday, December 17th. Eight equities research analysts have rated the stock with a hold rating, ten have assigned a buy rating and two have assigned a strong buy rating to the company. According to data from MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and an average price target of $49.94.

Hedge Funds Weigh In On Apellis Pharmaceuticals

A number of institutional investors have recently made changes to their positions in APLS. Wolverine Asset Management LLC bought a new stake in shares of Apellis Pharmaceuticals in the third quarter worth $27,000. True Wealth Design LLC bought a new stake in shares of Apellis Pharmaceuticals in the 3rd quarter worth about $27,000. Capital Performance Advisors LLP acquired a new stake in shares of Apellis Pharmaceuticals in the 3rd quarter valued at about $56,000. KBC Group NV raised its stake in shares of Apellis Pharmaceuticals by 34.8% in the 3rd quarter. KBC Group NV now owns 2,632 shares of the company’s stock valued at $76,000 after purchasing an additional 679 shares in the last quarter. Finally, Mirae Asset Global Investments Co. Ltd. lifted its position in shares of Apellis Pharmaceuticals by 21.6% during the third quarter. Mirae Asset Global Investments Co. Ltd. now owns 4,404 shares of the company’s stock worth $130,000 after purchasing an additional 781 shares during the last quarter. 96.29% of the stock is owned by institutional investors and hedge funds.

About Apellis Pharmaceuticals

Apellis Pharmaceuticals, Inc, a commercial-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutic compounds through the inhibition of the complement system for autoimmune and inflammatory diseases. It offers EMPAVELI for the treatment of paroxysmal nocturnal hemoglobinuria, C3 glomerulopathy and immune complex membranoproliferative glomerulonephritis, and hematopoietic stem cell transplantation-associated thrombotic microangiopathy; and SYFOVRE for treating geographic atrophy secondary to age-related macular degeneration and geographic atrophy (GA).